Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments 中文版
28 Sep, 2016 (Wednesday)

            
UMP(722)
Analysis:
UMP Healthcare Holdings (722) announced the introduction of NWS as a new JV partner into the UMP Phoenix JV. The Group's collaboration with NWS and Phoenix will facilitate the Group in the development of the general clinic network in Beijing-Tianjin-Hebei of the PRC and its healthcare business in the PRC. The Group's first new Shanghai clinic, UMP Xintiandi Medical Centre, has commenced operations in late July 2016 and its first new Beijing clinic, UMP Beijing Cai Fu Medical Centre, will commence operations in October 2016. Additionally, its two other clinics are in the final stage of licence application. (I do not hold the above stock)
Strategy:
Buy-in Price: $1.20, Target Price: $1.35, Cut Loss Price: $1.13

BROADGREENSTATE(1253)
Analysis:
Broad-Greenstate primarily devotes itself to construction services of municipal and landscaping projects. Its major clients include national and local governments as well as state-owned enterprises, who contribute to more than 90% of the company`s revenues. In the past five years, the company`s results maintained a high growth, with the compound annual growth rates of the company`s revenues and net profits between 2011 and 2015 reaching 28.6% and 51.3%, respectively. In H1 2016, the company announced 3 PPP projects totaling RMB1.8 billion. One of the three projects started construction during the period, whereas the other two projects will start construction in 2017. It is projected to drive substantial increase in the revenues of the next two years. Additionally, after the acquisition of Shanghai DTG Architectural Engineering Design Co., Ltd., the company`s architectural design capability and ability to undertake PPP projects have been further sharpened. Hence, it is believed that the company will be able to win more orders of PPP projects in the future.
Strategy:
Buy-in Price: $1.52, Target Price: $1.92, Cut Loss Price: $1.32


SMIC (981.HK) - Growth Prospects Remaining Optimistic in H2

Q2 Results Surpasses Expectation

In H1, SMIC's revenue and net profit reached USD1.33 billion and USD160 million, respectively, representing y-o-y increase of 25.4% and 20.3%, respectively. In Q2, its revenue was USD690 million, increased by 26.3% y-o-y and by 8.8% q-o-q. Its net profit amounted to USD97.64 million, up by 27.3% y-o-y and by 59% q-o-q. Revenue and net profit both went up to a new peak and surpassed the market expectation.

Domestic market growth is the main reason why the company could surpass its expectation. In Q2, the revenue from China increased by 28.7% y-o-y and by 20.1% q-o-q. Meanwhile, the company has its profitability rising. In Q2, gross profit margin was 31.6%, up by 7.3% q-o-q and by 2.2% y-o-y. This was due to the improved overall operational efficiency and the increase of the proportion of 40/45nm product. Besides, the outage of Beijing plant dragged down the gross profit margin in Q1.

Growth Prospects Remaining Optimistic in H2

It is expected that in Q3, the company will continue to see an increase of revenue by 8%-11%, and gross profit margin at 28%-30%. Revenue in Q4 will also continue to grow against the head wind. We believe that the growth of Chinese market and the enhancement of competitive edge in semi-conductor are the main force which drives the development of the company. Currently, Chinese system companies have gained much market share in the end market. Chip design companies surge rapidly. SMIC leads domestic integrated circuit production and is bound to be favored by the trend of growth in the integrated circuit industry in China.

Acquisition of LFoundry to Complement Each Other

SMIC acquired 70% of the shares of LFoundry at EUR49 million. Both will complement each other's advantages in terms of technology, product, talent, and market. The transaction has been completely closed in the end of July. It is the first transnational production base made by an integrated circuit wafer manufacturer in China. LFoundry is a wafer OEM in Italy. The capacity of 8-inch equivalent wafers surpassed 40,000 pieces. After merger, SMIC's capacity is expected to be increased by 13%. Meanwhile, LFoundry is committed to automotive and industrial application. Compared with the market positioning of SMIC in telecommunication and consumption market, its market application will be expanded.

Valuation

The company has been making money for 17 consecutive quarters. The migration of the electronics to the mainland, the capacity expansion, and the merger with LFoundry will support the company's continuing growth. Also, the advanced processing and integrated layout will sharpen the company's competitive edge. Therefore, we give a valuation of 1.2x BVPS in 2016 and the target price of HK$1, with the "Accumulate" rating. (Closing price as at 26 Sep 2016)

Risks

28nm mass production schedule falls short of expectation;

Growth of domestic customers falls short of expectation;

International integration falls short of expectation.

Financials

Click Here for PDF format...




Recommendation on 28-9-2016
RecommendationAccumulate
Price on Recommendation Date$ 0.860
Suggested purchase priceN/A
Target Price$ 1.000
Writer Info
Fan Guohe
(Research Analyst)
Tel: (86) 21 51699400-110
Email:
fanguohe@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre


Stock Borrowing & Lending



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong 輝立研究部 – 香港及中國
Company Stock Code Last Update Suggestion Target Price Price on Recom
Information Techology Research Department N/A+852 2277 6527research@phillip.com.hk
O-Net Technologies87727/09/2016No Rating4.02
O-Net communications87726/10/2010BUY7.156
Transportation and Automobiles Zhang Jing (86) 2151699200-103zhangjing@phillip.com.cn
CAR Inc69923/09/2016Accumulate9.618.28
Yutong60006615/09/2016Buy2722.07
Insurance Research Department (86) 21 51699400-110research@phillip.com.cn
Media & Publishing Research Department (+ 86 21 51699400-107)research@phillip.com.cn
Wisdom Sports Group166111/07/2016Buy3.32.18
NetDragon77716/06/2016Buy28.422.9
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
China Traditional Chinese Medicine57013/09/2016Accumulate4.43.98
China Traditional Chinese Medicine57012/09/2016Accumulate4.43.98
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Essex Bio-Technology106122/09/2016Buy4.523.62
Essex Bio-Technology106121/09/2016Buy4.523.62
New Energy Research Department (86) 21 51699400-110research@phillip.com.cn
Yunnan Water683923/05/2016Buy5.73.94
Grandblue ENV60032320/04/2016Buy 17.513.11
Food, Beverage and Retail Research Department (86) 21 51699400-110research@phillip.com.cn
361 Degrees136126/08/2016Buy3.22.48
Poly Culture363625/08/2016Accumulate23.519.84
Telecommunications Fan Guohe + (86) 21 51699400-110fanguohe@phillip.com.cn
SMIC98128/09/2016Accumulate1.000.000
Byaa Interactive43405/07/2016Accumulate32.71
Mainland Property Research Department (86) 21 51699400-110research@phillip.com.cn
天德化工60906/09/2016暫無評級1.95
Fortune REIT77823/08/2016No Rating9.65
Utilities Research Department (86) 21 51699400-110research@phillip.com.cn
Dynagreen133026/09/2016Buy5.524.14
Beijing Enterprises Water Group Limited37120/09/2016BUY7.25.46
Software & Service Research Department (86) 21 51699400-110research@phillip.com.cn
Goldpac Group331518/02/2015N/A4.77
IGG800221/11/2014Accumulate3.953.44
Hotels and Entertainment Zhang Jing (+ 86 51699400-103)zhangjing@phillip.com.cn
Jinjiang Hotels200608/07/2016Accumulate2.982.49
CUTC60035808/03/2016N/A10.41

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2016 Phillip Securities (HK) Ltd. All Rights Reserved.